

Ziopharm Oncology, Inc.

2021 Annual Shareholders Meeting

Wednesday, May 19, 2021, 9:00 am Eastern Time

Proposals

1. To elect the seven nominees for director named in the proxy statement to hold office until the 2022 annual meeting of stockholders and until their successors are duly elected and qualified
2. To ratify the selection by the audit committee of the board of directors of RSM US LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021
3. To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement
4. To approve an amendment to the Company's amended and restated certificate of incorporation to increase the authorized number of shares of common stock from 250,000,000 shares to 350,000,000 shares

Remarks by
Heidi Hagen,
Interim Chief
Executive
Officer



Unprecedented Transformation in Past Six Months

From...

Scientifically-directed strategy

Broad portfolio including high complexity programs in small market opportunities

Shareholder / Company disconnect and mis-alignment between Board, management

No clinical work initiated by JV Partner Eden BioCell for CD19 RPM CAR-T Program

No Company-directed TCR-T clinical work ongoing

Houston GMP Facility construction in process

...To



Clinical development and operationally directed strategy



Focused, capital efficient portfolio addressing high unmet need, large patient populations, and significant market sizes



Refreshed Board with significant shareholder representation guiding management; multiple high caliber, operationally savvy candidates for CEO position being evaluated by Board



Cleared IND in Taiwan with patient treatment underway; multiple patients successfully treated under IIT / Compassionate Use in China



Cleared FDA IND for Phase I/II trial, with manufacturing preparation and patient pre-screening underway



GMP Facility construction complete with qualification and validation work commencing shortly

Q&A with Executive Chairman James Huang and Interim Chief Executive Officer Heidi Hagen

